Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Setmelanotide - Rhythm

Drug Profile

Setmelanotide - Rhythm

Alternative Names: BIM-22493; CAM 4072; RM-493

Latest Information Update: 16 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ipsen
  • Developer Charite - Universitatsmedizin Berlin; Ipsen; Rhythm
  • Class Amides; Antihyperglycaemics; Cyclic peptides; Cysteines; Disulfides; Obesity therapies
  • Mechanism of Action Melanocortin type 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Prader-Willi syndrome; Obesity
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Obesity
  • No development reported Diabetes mellitus

Most Recent Events

  • 06 Jan 2020 Rhythm plans to submit rolling NDA for Obesity with the US FDA in the first quarter of 2020
  • 07 Aug 2019 Rhythm Pharmaceuticals announces intention to submit MAA to the European Medicines Agency for Obesity
  • 07 Aug 2019 Efficacy and safety data from two phase III trials in Obesity released by Rhythm Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top